HealthcareServices

Global Cancer Gene Therapy Market Size Projected to Reach $7.67 Billion During the Forecast Period

November 20, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Cancer Gene Therapy Market Over The Five-Year Period 2025–2029?

The cancer gene therapy market size has seen rapid expansion in recent years. It is anticipated to increase from $3.61 billion in 2024 to $4.21 billion in 2025, achieving a compound annual growth rate (CAGR) of 16.6%. This historical growth is attributable to several key factors, including a rising awareness of oncovirus-related cancers, an increase in collaborations between biotechnology firms and academic institutions, heightened clinical trial activity for early-phase gene therapies, a growing demand for ex vivo modified cell therapies, and a surge in strategic licensing agreements for gene therapy platforms.

The cancer gene therapy market size is projected to experience substantial growth in the near future, forecast to reach $7.67 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 16.2%. This anticipated expansion during the forecast period is primarily driven by an increased emphasis on non-viral delivery methods, wider access to companion diagnostics, a burgeoning interest in readily available off-the-shelf allogeneic cell therapies, the expanding role of contract development & manufacturing organizations (CDMOs), and advancements in synthetic biology facilitating customizable gene circuits. Furthermore, key trends anticipated during this period encompass progress in non-viral gene delivery platforms, enhanced manufacturing automation for gene therapy production, the creation of synthetic promoters for specific cancer expression, novel approaches in intratumoral gene therapy administration, and the formulation of multiplexed gene modulation strategies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27233&type=smp

What Are The Top Growth Drivers Impacting The Cancer Gene Therapy Market Outlook?

A rising occurrence of cancer is anticipated to fuel the expansion of the cancer gene therapy market in the future. Cancer is characterized as a condition involving the uncontrolled multiplication of abnormal cells, which can invade and spread to various parts of the body, originating in diverse tissues and organs, and classified according to its cellular or tissue source. The growing number of cancer cases is attributed to increasing life expectancy, as the risk of developing cancer rises with age. Cancer gene therapy offers treatment by modifying or replacing faulty genes to halt cancer cell growth or to enhance the immune system’s ability to destroy them. For example, Macmillan Cancer Support, a UK-based organization, reported in August 2024 that more than 3 million people in the UK are living with cancer. This figure is projected to reach 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the increasing incidence of cancer is a key driver for the growth of the cancer gene therapy market.

How Is The Cancer Gene Therapy Market Segmented?

The cancer gene therapy market covered in this report is segmented

1) By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer

2) By Indication: Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Other Indications

3) By Vector Type: Lentivirus, RetroVirus And Gamma RetroVirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, Other Vector Types

4) By End-User: Hospitals, Research Institutes, Biopharma Companies, Diagnostic centers, Other End Users

Subsegments:

1) By Gene Induced Immunotherapy: CAR-T Cell Therapy, TCR (T-Cell Receptor) Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell-Based Gene Therapy, NK Cell Gene Therapy

2) By Oncolytic Virotherapy: Adenoviruses, Herpes Simplex Virus (HSV), Reovirus, Vaccinia Virus, Newcastle Disease Virus (NDV)

3) By Gene Transfer: Viral Gene Transfer, Non-Viral Gene Transfer

Which Market Trends Are Creating New Opportunities In The Cancer Gene Therapy Industry?

Leading companies in the cancer gene therapy market are concentrating on developing innovative treatments, such as CAR-T cell therapy, to enhance therapeutic accuracy, improve patient outcomes, and more effectively target cancer cells while minimizing harm to healthy tissues. CAR-T therapy is a sophisticated immunotherapy method where a patient’s immune cells are genetically engineered to better detect and eliminate cancer cells by integrating specialized receptors onto them. For instance, in April 2024, ImmunoACT, an India-based biotechnology company, unveiled NexCAR19 (actalycabtagene autoleucel), marking it as India’s first domestically developed CAR-T cell therapy for cancer. Specifically designed to address B-cell lymphomas and leukemias, NexCAR19 operates by reprogramming a patient’s own T cells to recognize and destroy malignant cells. Built upon advanced chimeric antigen receptor (CAR) technology, the therapy is manufactured locally, thus making it more affordable and accessible compared to imported options. This launch represents a significant milestone for India’s presence in the global cancer gene therapy arena, emphasizing notable strides in indigenous innovation and personalized cancer care.

Which Major Firms Are Strengthening Their Position In The Cancer Gene Therapy Industry?

Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, Biogen Inc., Sarepta Therapeutics Inc., AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, and Abeona Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report

What Are The Regional Market Dynamics Impacting The Cancer Gene Therapy Industry?

North America was the largest region in the cancer gene therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Cancer Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27233&type=smp

Browse Through More Reports Similar to the Global Cancer Gene Therapy Market 2025, By The Business Research Company

Mortgage Lender Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/mortgage-lender-global-market-report

Property And Casualty Insurance Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/property-and-casualty-insurance-global-market-report

Home Insurance Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/home-insurance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795